Rapport Therapeutics Appoints Chief People Officer

BOSTON, Mass. and SAN DIEGO, Calif. – February 28, 2024 – Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Kathy Wilkinson as Chief People Officer.

“Bringing Kathy on board as our Chief People Officer is tremendously exciting as the Rapport team rapidly expands,” said Abraham Ceesay, Chief Executive Officer of Rapport. “Any company’s success requires top talent and a vibrant culture, and Kathy has the experience and vision to ensure that Rapport will incorporate those two crucial ingredients as it advances its programs. With Kathy as the custodian of our growing and evolving team and culture, we are sure to have the right people and resources in place to achieve our goals as a clinical-stage biotech company.”

With over 20 years of experience, Kathy comes to Rapport from 2seventy bio, where she was Chief People Officer. The 250-person company was spun out from bluebird bio, where Kathy served in a variety of human resource roles – most recently Chief People Officer – for nearly a decade. At bluebird, Kathy led the development of a unique, people-focused culture to support the growth of the company into a fully integrated global biotech with four approved products. Prior to her time at bluebird, Kathy served in several People and Culture leadership roles including at Adnexus, a Bristol-Meyers Squibb Company, and Codon Devices. Kathy earned her B.A. in Sociology from Harvard University.

“I’ve spent the majority of my career in the biotech sector, and I know how driven this community is to creating lasting and positive impact on patients’ lives. Rapport is a prime example of the biotech mission in action,” said Ms. Wilkinson. “As the Rapport team executes its transformative vision for precision neuromedicine, we are building a culture that nurtures its core values and values our people while attracting and investing in diverse talent and ideas. I am eager to join this group and lead this important work of building a team that will make Rapport’s vision a reality for patients.”

About Rapport (www.rapportrx.com)

Rapport is developing a new class of precision neuromedicines that could give patients better alternatives to current treatments for neurological and psychiatric diseases, which often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance and discontinuation. By more precisely targeting the neural circuits and cell types where diseases originate, Rapport’s approach has the potential to reduce the unwanted drug-target interactions that lead to these issues. The company’s platform, built and refined over the past decade by its founding scientific team, achieves precision through the discovery and targeting of receptor-associated proteins, or RAPs, which display regional or neural circuit-specific expression. Rapport has ongoing clinical trials and discovery-stage programs in epilepsy, hearing, pain, and psychiatric disorders.



Kit Rodophele
Ten Bridge Communications